HZX-02-059
/ Xiamen University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2024
Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
(PubMed, Curr Med Sci)
- "Overall, these findings suggest that HZX-02-059 is a promising agent for the treatment of B-ALL patients resistant to conventional therapies."
Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • MYC
1 to 1
Of
1
Go to page
1